Endo pays $2.3m to settle states antitrust claims

22-07-2019

Sarah Morgan

Endo pays $2.3m to settle states antitrust claims

designer491 / Shutterstock.com

Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm (Lidocaine patch 5%) off the market.   


Endo Pharmaceuticals, generics, pay-for-delay, Lidoderm, settlement agreement, antitrust, competition

LSIPR